Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

Clinical Microbiology and Infection

Volumn 15, Issue 3, 2009, Pages 274-279

  Ghannoum, Mahmoud A ^a   Chen, A ^b,c   Buhari, M ^c   Chandra, J ^a   Mukherjee, P K ^a   Baxa, D ^b   Golembieski, A ^b   Vazquez, J A ^b,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal; Candida; Cross resistance; Echinocandins; Fungi; Hot spot mutation

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FUNGAL PROTEIN; MICAFUNGIN; PROTEIN FKSI; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BURN UNIT; CANDIDA PARAPSILOSIS; CELL DAMAGE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNGAL CELL; FUNGUS ISOLATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

CANDIDA; CANDIDA PARAPSILOSIS; FUNGI;

EID: 63249086820     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02660.x     Document Type: Article

References (37)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239-244.
3. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-425.
4. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
5. Posteraro B, Bruno S, Boccia S et al. Candida parapsilosis bloodstream infection in pediatric oncology patients: Results of an epidemiologic investigation. Infect Control Hosp Epidemiol 2004; 25: 641-645.
6. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21.
7. Hedderwick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis 2000; 19: 663-670.
8. Chen CM, Ho MW, Yu WL, Wang JH. Fungal peritonitis in peritoneal dialysis patients: Effect of fluconazole treatment and use of the twin-bag disconnect system. J Microbiol Immunol Infect 2004; 37: 115-120.
9. Chen K-H, Chang C-T, Yu C-C, Huang J-Y, Yang C-W, Hung C-C. Candida parapsilosis peritonitis has more complications than other Candida peritonitis in peritoneal dialysis patients. Ren Fail 2006; 28: 241-246.
10. Manzano-Gayosso P, Hernandez-Hernandez F, Mendez-Tovar LJ, Gonzalez-Monroy J, Lopez-Martinez R. Fungal peritonitis in 15 patients on continuous ambulatory peritoneal dialysis (CAPD). Mycoses 2003; 46: 425-429.
11. Wang AY, Yu AW, Li PK et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000; 36: 1183-1192.
12. Darwazah A, Berg G, Faris B. Candida parapsilosis: An unusual organism causing prosthetic heart valve infective endocarditis. J Infect 1999; 38: 130-131.
13. Divekar A, Rebekya IM, Soni R. Late onset Candida parapsilosis endocarditis after surviving nosocomial candidemia in an infant with structural heart disease. Pediatr Infect Dis J 2004; 23: 472-475.
14. Jones JM, Sarsam MA, Clarke MA, Hedderwick SA. Candida parapsilosis: Two cases of endocarditis in association with the Toronto stentless porcine valve. J Infect 2002; 44: 196-198.
15. Kaloterakis A, Rizos I, Goumas G et al. Isolated native tricuspid valve Candida endocarditis in a non-drug-addicted patient: Case report and review of the literature. J Heart Valve Dis 2003; 12: 652-658.
16. Arevalo MP, Carrillo-Munoz AJ, Salgado J et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: A comparative study with M27-A microdilution method. J Antimicrob Chemother 2003; 51: 163-166.
17. Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008; 59: 361-379.
18. Wiederhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12: 1313-1333.
19. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-769.
20. Baixench M-T, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in Candida albicans: Case report and review. J Antimicrob Chemother 2007; 59: 1076-1083.
21. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-1383.
22. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-2894.
23. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-2063.
24. Bonassoli LA, Bertoli M, Svidzinski TIE. High frequency of Candida parapsilosis on the hands of healthy hosts. J Hosp Infect 2005; 59: 159-162.
25. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med 1993; 94: 577-582.
26. Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol 2006; 44: 4342-4344.
27. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 2nd edn. CLSI document M27-A2. Wayne, PA:: CLSI, 2002.
28. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: Analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46: 2620-2629.
29. Chandra J, Mukherjee PK, Leidich SD et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80: 903-908.
30. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-130.
31. Park S, Wong M, Marras SA et al. Rapid identification of Candida dubliniensis using a species-specific molecular beacon. J Clin Microbiol 2000; 38: 2829-2836.
32. Kahn JN, Garcia-Effron G, Hsu M-J, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-1878.
33. Pasquale T, Tomada JR, Ghannoum M, Dipersio J, Bonilla H. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 2008; 61: 219.
34. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-708.
35. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-3273.
36. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-2524.
37. Cross EW, Park S, Perlin DS. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 2000; 6: 155-161.